The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function intype 2 diabetes

Journal of Korean Medical Science

Volumn 27, Issue 11, 2012, Pages 1364-1370

  Kubota, Yoshiaki ^a   Miyamoto, Masaaki ^a   Takagi, Gen ^a   Ikeda, Takeshi ^a   Sonoko, Kirinoki Ichikawa ^a   Tanaka, Kotoko ^a   Mizuno, Kyoichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Adiponectin; Dipeptidyl peptidase 4 inhibitor; Endothelial function; Type 2 diabetesmellitus

Indexed keywords

ADIPONECTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCERYL TRINITRATE; PYRAZINE DERIVATIVE; SITAGLIPTIN; TRIAZOLE DERIVATIVE; VASODILATOR AGENT;

AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; REGRESSION ANALYSIS; VASCULAR ENDOTHELIUM; VASODILATATION;

ADIPONECTIN; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROGLYCERIN; PROSPECTIVE STUDIES; PYRAZINES; REGRESSION ANALYSIS; TRIAZOLES; VASODILATION; VASODILATOR AGENTS;

EID: 84872565644     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2012.27.11.1364     Document Type: Article

References (38)

1. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75.
2. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105: 546-9.
3. Rossi R, Nuzzo A, Origliani G, Modena MG. Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women. J Am Coll Cardiol 2008; 51: 997-1002.
4. Witte DR, Westerink J, de Koning EJ, van der Graaf Y, Grobbee DE, Bots ML. Is the association between flow-mediated dilation and cardiovascular risk limited to low-risk populations? J Am Coll Cardiol 2005; 45: 1987-93.
5. Pepine CJ. The impact of nitric oxide in cardiovascular medicine: untapped potential utility. Am J Med 2009; 122: S10-5.
6. Goligorsky MS. Endothelial cell dysfunction: can't live with it, how to live without it. Am J Physiol Renal Physiol 2005; 288: F871-80.
7. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113: 1708-14.
8. Higashi Y, Sasaki S, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, Matsuura H, Kajiyama G, Oshima T. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol 2000; 35: 284-91.
9. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40: 505-10.
10. Frick M, Alber HF, Hugel H, Schwarzacher SP, Pachinger O, Weidinger F. Short- and long-termchanges of flow-mediated vasodilation in patients under statin therapy. Clin Cardiol 2002; 25: 291-4.
11. Papathanassiou K, Naka KK, Kazakos N, Kanioglou C, Makriyiannis D, Pappas K, Katsouras CS, Liveris K, Kolettis T, Tsatsoulis A, et al. Pioglitazone vs glimepiride: differential effects on vascular endothelial function in patients with type 2 diabetes. Atherosclerosis 2009; 205: 221-6.
12. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-39.
13. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 14843-7.
14. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003; 114: 115-21.
15. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-7.
16. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. Improvement of postprandial endothelial function after a single dose of exena-tide in individuals with impaired glucose toleranceand recent-onset type 2 diabetes. Diabetes Care 2010; 33: 1028-30.
17. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006; 317: 1106-13.
18. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-15.
19. Tsuchiya K, Akaza I, Yoshimoto T, Hirata Y. Pioglitazone improves endothelial function with increased adiponectin and high-density lipopro-tein cholesterol levels in type 2 diabetes. Endocr J 2009; 56: 691-8.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulinconcentrations in man. Diabetologia 1985; 28: 412-9.
21. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.
22. Lee JW, Lee HR, Shim JY, Im JA, Kim SH, Choi H, Lee DC. Viscerally obese women with normal body weight have greater brachial-ankle pulse wave velocity than nonviscerally obese women with excessive body weight. Clin Endocrinol (Oxf) 2007; 66: 572-8.
23. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
24. Woodman RJ, Playford DA, Watts GF, Cheetham C, Reed C, Taylor RR, Puddey IB, Beilin LJ, Burke V, Mori TA, et al. Improved analysis of brachial artery ultrasound using a novel edge-detection software system. J Appl Physiol 2001; 91: 929-37.
25. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962-5.
26. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110: 955-61.
27. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocar-dial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010; 298: H1454-65.
28. Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 2007; 11: 115-21.
29. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-7.
30. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Cayci T, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, et al. Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? Nephrol Dial Transplant 2010; 25: 3250-6.
31. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 366-73.
32. Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hyper-tension. J Clin Pharmacol 2008; 48: 592-8.
33. Rossi R, Cioni E, Nuzzo A, Origliani G, Modena MG. Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care 2005; 28: 702-7.
34. Rizza S, Cardellini M, Porzio O, Pecchioli C, Savo A, Cardolini I, Senese N, Lauro D, Sbraccia P, Lauro R, et al. Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. Atherosclerosis 2010; 215: 180-3.
35. Chen LL, Yu F, Zeng TS, Liao YF, Li YM, Ding HC. Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes. Eur J Pharmacol 2011; 659: 296-301.
36. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P,Creager MA, Yeung AC, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-41.
37. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010; 12: 485-94.
38. Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, Chen R, Wolf R, Mahaffey KW. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010; 122: 16-27.